SH5-07 is a selective inhibitor of the enzyme soluble epoxide hydrolase (sEH), which plays a key role in the metabolism of endogenous epoxy fatty acids, particularly those derived from arachidonic acid. By inhibiting sEH, SH5-07 helps maintain higher levels of these protective epoxy metabolites, which have anti-inflammatory, analgesic, and vasodilatory effects. It is primarily used in research settings to study inflammatory pathways, pain mechanisms, and cardiovascular function. SH5-07 has shown potential in preclinical models for reducing neuropathic and inflammatory pain, making it a compound of interest in the development of non-opioid analgesics. It is also investigated for its protective effects in models of hypertension, stroke, and kidney disease due to its ability to modulate vascular and inflammatory responses. Due to its blood-brain barrier permeability, SH5-07 is particularly valuable in neuroscience research, where central nervous system activity is required. Its use supports the exploration of sEH as a therapeutic target across a range of chronic diseases involving inflammation and oxidative stress.